Vyaire Medical today announced its support of a study to measure the short- and long-term impacts of COVID-19 pneumonia. The single-center, investigator-initiated study at Amphia Hospital in Breda, the Netherlands led by Ingrid de Backer, MD, PhD, will contribute to much-needed data on the effects of COVID-19 after hospital discharge, both in terms of pulmonary function and quality of life.

“At Vyaire, we ramped up production at unprecedented rates to meet the demand for ventilators and other supplies when the pandemic began, but our commitment to the respiratory care community in understanding this novel coronavirus doesn’t stop there,” said Michael Pedro, M.D., vice president and chief medical officer, Vyaire. “Through this unrestricted grant, we take just one more step in providing clarity on this disease and the ongoing effects, as so much remains unknown.”

The study, titled “pulmonary function and health-related quality of life after COVID-19 pneumonia,” evaluated 101 adult COVID-19 patients with either moderate or severe pneumonia at six weeks and three months post-hospitalization. At both of those time points, the study mapped:

• lung function and degree of dyspnea
• quality of life, anxiety and depression
• effort and muscle strength
• differences between ICU and non-ICU patients in lung function, quality of life and exercise capacity

Results of the patients at six-week post-discharge were recently published in Respiratory Medicine and will be followed by three-month post-discharge data.  

For more information about Vyaire’s response to the COVID-19 crisis, visit the company’s COVID-19 Response Center.